1NE0 Stock Chart & Stats
€4.15
-€0.18(-3.70%)
At close: 4:00 PM EDT
€4.15
-€0.18(-3.70%)
Day’s Range― - ―
52-Week Range€2.78 - €7.60
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€68.65M
Enterprise Value€121.00
Total Cash (Recent Filing)€11.20M
Total Debt (Recent Filing)€1.81M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 09, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding17,178,785
10 Day Avg. Volume0
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.85Price Target Upside185.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.74
Revenue Forecast (FY)€21.35M
Bulls Say, Bears Say
Bulls Say
YCANTH Commercial MomentumRising YCANTH revenue and applicator volumes indicate strengthening prescriber adoption and product utilization. Continued commercial execution can expand the company’s recurring product-revenue base, improve operating leverage, and support broader market penetration over the next several quarters.
Strong Product EconomicsGross margins above 90% demonstrate attractive unit economics for YCANTH and provide substantial contribution potential as sales scale. Margin durability gives management more capacity to fund commercialization and development, although overall profitability still depends on controlling operating expenses.
Partner-supported Pipeline ExpansionExternal funding and international partnerships broaden Verrica’s commercial reach while reducing the company’s direct burden for major development spending. These arrangements preserve global rights outside Japan and Israel and create additional pathways for future product and milestone revenue.
Bears Say
Persistent UnprofitabilityThe company’s high product margins have not yet translated into sustainable earnings because operating costs remain well above the current revenue base. Continued losses reduce internal funding capacity and make successful commercialization, expense discipline, and future financing increasingly important.
Ongoing Cash ConsumptionPersistent operating and free-cash-flow deficits mean Verrica is not yet self-funding its business or development programs. Continued cash consumption can constrain strategic flexibility and increase dependence on external capital until product revenue grows enough to cover operating and research expenses.
Revenue Volatility And ContractionThe recent top-line contraction highlights volatility in Verrica’s revenue base and its exposure to nonrecurring collaboration milestones. Even with improving YCANTH demand, the company must sustain product growth and replace milestone-driven revenue to establish a more predictable scale of operations.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €2.78 and its highest was €7.60 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is €68.65M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 52 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.532 earnings per share for the quarter, missing the consensus estimate of -€0.333 by -€0.199.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.43.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.532 in its last earnings report, missing expectations of -€0.333. Following the earnings report the stock price went down -2.668%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1NE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€11.85 (185.56% Upside)
€11.85 (185.56% Upside)
Blogger Sentiment
Neutral
DE:1NE0 Sentiment 100%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth €181.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
1NE0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of clear commercial momentum for YCANTH (robust unit growth, quarter-over-quarter revenue gains, new international distribution, and strong trial progress) and encouraging clinical signals (VP-315 Phase II abscopal effects and active Phase III enrollment for common warts). Offsetting these positives are sizable year-over-year revenue decline driven by last year’s one-time milestone, substantial GAAP and non-GAAP losses, materially higher R&D and SG&A expense, a legal settlement charge, and a relatively modest cash balance that makes the company reliant on a conditional credit facility. Management’s nondilutive financing and Torii’s substantial trial funding materially de-risk near-term liquidity and program funding, but financial outcomes remain contingent on milestone achievement, careful draw decisions, and successful trial readouts.View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
€11.85
▲(185.56% Upside)